99,700 Shares in LivaNova PLC (NASDAQ:LIVN) Purchased by Tri Locum Partners LP

Tri Locum Partners LP purchased a new position in LivaNova PLC (NASDAQ:LIVN) during the fourth quarter, HoldingsChannel reports. The institutional investor purchased 99,700 shares of the company’s stock, valued at approximately $4,617,000. LivaNova makes up about 1.0% of Tri Locum Partners LP’s holdings, making the stock its 26th largest holding.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its holdings in shares of LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after acquiring an additional 219 shares during the period. Sterling Capital Management LLC increased its position in LivaNova by 800.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after purchasing an additional 1,441 shares during the last quarter. Central Pacific Bank Trust Division raised its stake in LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after purchasing an additional 720 shares during the period. Sanctuary Advisors LLC acquired a new position in shares of LivaNova in the 3rd quarter valued at $219,000. Finally, Vestcor Inc purchased a new stake in shares of LivaNova during the 4th quarter valued at $204,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on LIVN shares. Mizuho reduced their target price on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Barclays decreased their target price on LivaNova from $58.00 to $56.00 and set an “equal weight” rating for the company in a report on Friday, March 7th. Stifel Nicolaus cut their price target on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. The Goldman Sachs Group decreased their price objective on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $64.00 target price on shares of LivaNova in a research note on Monday, March 17th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $61.17.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $37.26 on Friday. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of 88.71 and a beta of 0.90. The company has a 50 day moving average of $38.94 and a two-hundred day moving average of $46.14. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $64.48. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.